sur INTEGRAGEN (EPA:ALINT)
IntegraGen: two takeover bids filed in receivership
On September 11, 2026, IntegraGen, a genomics specialist, announced it had received two takeover bids as part of its insolvency proceedings initiated on June 15, 2026. The proposals came from Health In Code and ABL Diagnostics. They concern the acquisition of operations and assets through a sale plan. Details remain confidential for the time being.
The offers, financed with equity, require additional information, particularly regarding contracts and financial commitments. Conditions precedent, such as internal audits and approvals, still need to be met. None of the offers include a share buyback program, leaving shareholders exposed to potential losses.
The Commercial Court of Évry will rule on these offers at the hearing on October 5, 2026. IntegraGen's business continuity is assured, without interruption for its clients. The company remains committed to its ongoing projects.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INTEGRAGEN